ABSTRACT
INTRODUCTION
of cells were positive for total Gn which were again similar to the DMSO control (Fig. 2F ). The 126 same experiment was conducted to determine total levels of N protein and no significant change 127 in total protein levels with sorafenib treatment was observed (Fig. 2G) . Collectively, these results
128
reaffirm the hypothesis that sorafenib impedes the viral egress stage of the RVFV life cycle 129 while exhibiting no significant change in viral protein production at 12 hpi. and the localization of the virions in the respective conditions. As expected, when treated with 138 DMSO, we observe several small vesicles containing virus particles, which we can reasonably 139 deduce are Golgi vesicles containing virions being transported towards the plasma membrane to 140 be exocytosed (Fig. 3A) . After sorafenib treatment, the appearance of large intracellular vacuoles 141 TR-17-166 Distribution Statement A: Approved for public release; distribution is unlimited.
containing virions was observed (Fig. 3B ). It has been reported in the literature that sorafenib 142 alters critical organelles of the secretory pathway as exemplified by the fragmentation of the 143 Golgi complex (14) and dilated ER lumens indicative of ER stress (15). Thus, we can 144 hypothesize that the vacuoles observed could be dilated ER or Golgi. Another possibility is that 145 they might be the result of membranes fusing together, unable to further vesiculate. These results
146
indicate that in the presence of sorafenib, RVFV is being trapped within these large intracellular 147 vacuoles, which correlates with the observed decrease in viral egress. Gn staining pattern, with Gn no longer colocalizing with the Golgi (Fig. 4B , 5B). Additionally, 157 the morphology of the Golgi is altered with sorafenib treatment, displaying a more fragmented 158 appearance as has been previously observed in the literature (14). Thus, the aberrance in viral 159 egress caused by sorafenib could be the result of the virions not being retained in the Golgi.
161
Given that sorafenib treatment prevented Gn from colocalizing with the Golgi, we hypothesized 162 that it was relocated to another location within the secretory pathway. To test this hypothesis, Gn 163 localization to the ER and/or autophagasomes was analyzed using calnexin and p62 as markers 164 TR-17-166 Distribution Statement A: Approved for public release; distribution is unlimited.
of ER and autophagasomes, respectively. Infected Vero (Fig. 6A) and Huh7 (Fig. 7A ) cells 165 treated with DMSO displayed the characteristic perinuclear Gn staining of RVFV infected cells.
166
There was a low level of colocalization with Gn and the ER marker calnexin (Fig. 6A, 7A ), 167 which is not surprising as Gn is translated on the rough ER. However, sorafenib treated cells 168 exhibited a far greater level of colocalization with the ER as indicated by the prevalence of 169 yellow staining compared to the DMSO control (Fig. 6B, 7B ). Gn colocalization with p62 was 170 not observed (data not shown), suggesting that Gn does not relocate to autophagosomes 171 following sorafenib treatment. So far, our overall data supports the idea that in the presence of 172 sorafenib, assembly of RVFV virions occurs in the Golgi, but prevents them from egressing by 173 redirecting them to the ER after assembly where they remain. replication in our previously published research (10). Therefore, we carried out an in-depth 178 literature search to identify a candidate sorafenib target protein, which would induce the effects 179 on the secretory pathway that are being observed, leading to the subsequent block in viral egress.
180
One potential target of sorafenib is valosin-containing protein (VCP), a hexameric AAA+
181
ATPase (ATPases associated with diverse cellular activities), also known as p97. It has been 182 shown that sorafenib prevents the tyrosine phosphorylation of VCP inducing ER stress, 183 fragmentation of the Golgi, and disruption of the cellular secretory pathway (14).
184
To determine whether VCP is important for viral egress, VCP expression was knocked down 185 using siRNA and followed by RVFV infection. As a control, a very closely related AAA+ (Fig. 8B) . These results indicate that loss of VCP inhibits RVFV replication. (Fig. 8D) . Also, the siRNA knockdown of VCP proved to be robust as demonstrated by 206 the very faint staining of VCP (Fig. 8D) .
207
Since knockdown of VCP resulted in Gn staining that was analogous to the alteration in Gn (Fig. 11B ). These data demonstrate that loss of VCP inhibits 244 viral egress. This study is a follow up to our group's work on screening FDA-approved drugs to find a 247 therapeutic to combat RVFV infection. We found our top candidate sorafenib and our goal was 248 to ascertain the mechanism by which sorafenib inhibits RVFV replication and to determine one 249 of the host's cellular targets that RVFV hijacks to propagate itself. We discovered that sorafenib 250 was capable of inhibiting RVFV replication by impeding viral egress, while still allowing for 251 viral protein production and virion assembly to occur. Our data showed that sorafenib caused 252 virions to get trapped in large vesicles which we can conclude are formed from dilated ER since 253 viral Gn no longer colocalized with the site of budding, the Golgi, but rather colocalized with the 254 ER. and RVFV and the role that sorafenib plays in this interaction warrants further study.
306
Collectively our data has resulted in our working model of sorafenib mediated viral egress 307 inhibition (Fig. 12) . In the absence of sorafenib treatment (Fig. 12A ), viral proteins are translated 308 by ribosomes that are either free-floating in the cytoplasm or are embedded in the ER. Gn and Gc 309 are initially expressed as a precursor polypeptide which is then co-translationally cleaved, 310 leading to the maturation of both glycoproteins. Once matured, Gn and Gc form oligomers which 311 are transported from the ER to the Golgi apparatus due to the presence of a Golgi-targeting 312 TR-17-166 Distribution Statement A: Approved for public release; distribution is unlimited.
signal located within the Gn C-terminal sequence (9). Once the proteins are ready to move on to 313 the Golgi, ER-to-Golgi vesicles containing the viral proteins are able to form and are shuttled to 314 the Golgi. Within the Golgi, the Gn and Gc oligomers organize into the virus envelope as 315 cylindrical hollow spikes that cluster into an icosahedral lattice of 122 distinct capsomers.
316
Published data have revealed that distinct regions of the Gn cytosolic tail are required for binding In the presence of sorafenib treatment, the localization of Gn is dramatically altered (Fig. 12B ).
322
The majority of Gn now colocalizes with the ER. The large vacuoles containing virus that were 323 observed in the TEM images are hypothesized to be dilated ER. We also note fragmentation of 324 the Golgi complex as visualized in Fig. 4B . Since we observed fully assembled virions in the 325 TEM images (Fig. 3B ) and also detected a buildup of infectious virus particles within the cell 326 (10), we can infer that the virions are being allowed to assemble properly with sorafenib 327 treatment. This leads us to believe that the viral proteins are able to be transported from the ER 328 to the Golgi within vesicles to be assembled into virions within the Golgi. However, since the 329 majority of Gn was found to colocalize with the ER, we hypothesize that the assembled virions 330 were prevented from egressing to the plasma membrane due to the inhibited function of VCP. Recombinant RVFV strain (r)MP12 was rescued and titered as previously described (10).
343
Infections were performed under BSL-2 conditions. Cells were infected with virus at a plaque assay (23). The intracellular infectivity assay was performed as described in (10).
349
Sorafenib Tosylate (S1040) was purchased from Selleckchem and made into 10 mM stocks 
Transmission electron microscopy (TEM). Vero cells were infected with MP12 MOI 10
376 followed by treatment with sorafenib for 24h. Cells were then fixed and processed as described 377 in (25). TR-17-166 Distribution Statement A: Approved for public release; distribution is unlimited.
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